Spotlight
Announcing the International launch of Abbott Vascular's flagship drug
eluting stent system, the XIENCE V Everolimus
Eluting Coronary Stent System.* *CAUTION: XIENCE V is an investigational device. Limited by Federal (U.S.) law to investigational use only. |
|
|
|
Announcing HT-ADVANCE, the latest addition to Abbott Vascular's HI-TORQUE coronary guide wire product family. The HI-TORQUE ADVANCE is the first guide wire with a Drug-Eluting Stent (DES) device delivery indication. | |
|
|
Reimbursement Resource - Keep up with the latest information on coverage, coding and payment for coronary, carotid and other peripheral procedures related to Abbott Vascular devices. |
Investors & Media
- Abbott to Initiate First Study to Evaluate XIENCE™ V Everolimus Eluting Coronary Stent System in Treatment of Women with Cardiovascular Disease
- Abbott Statement Regarding CMS’ Proposed Expansion of Coverage for Carotid Artery Stenting
- Private-Label Version of Abbott's XIENCE™V Drug-Eluting Coronary Stent System Launches in Europe
View more news...
LT2922560 B